SCHEMBL29992091

SCHEMBL29992091

c1ccc(CN2CCN(Cc3ccccn3)CCN(Cc3ccccn3)CCN(Cc3ccccn3)CC2)nc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.71
CYP2C19 P33261 1/20 0.71
KMT2A Q03164 1/20 0.71
KDM4E B2RXH2 8/20 0.66
ALDH1A1 P00352 7/20 0.66
NPSR1 Q6W5P4 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.61
HRH1 P35367 1/20 0.60
TRPV6 Q9H1D0 1/20 0.60
MAPT P10636 1/20 0.59
TSHR P16473 1/20 0.59
MAPK1 P28482 1/20 0.59
SIGMAR1 Q99720 3/20 0.58
LMNA P02545 2/20 0.57
GFER P55789 1/20 0.57
GAA P10253 1/20 0.56
DDB1 Q16531 1/20 0.56
CRBN Q96SW2 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331974 1.00 CYP1A2 (0.71) CYP1A2CYP2C19KMT2AKDM4EALDH1A1
SCHEMBL20804356 1.00 CYP1A2 (0.71) CYP1A2CYP2C19KMT2AKDM4EALDH1A1
SCHEMBL30141847 1.00 CYP1A2 (0.71) CYP1A2CYP2C19KMT2AKDM4EALDH1A1
SCHEMBL1333260 1.00 CYP1A2 (0.71) CYP1A2CYP2C19KMT2AKDM4EALDH1A1
SCHEMBL8634159 0.94 CYP1A2 (0.65) CYP1A2CYP2C19KMT2AKDM4EALDH1A1
SCHEMBL1822554 0.92 CYP1A2 (0.67) CYP1A2CYP2C19KMT2AKDM4EALDH1A1
SCHEMBL31106560 0.92 CYP1A2 (0.67) CYP1A2CYP2C19KMT2AKDM4EALDH1A1
SCHEMBL18301469 0.91 CYP1A2 (0.66) CYP1A2CYP2C19KMT2AKDM4EALDH1A1
SCHEMBL1331614 0.91 CYP1A2 (0.66) CYP1A2CYP2C19KMT2AKDM4EALDH1A1
SCHEMBL6269839 0.91 CYP1A2 (0.66) CYP1A2CYP2C19KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4610269-A1 UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE 3B Pharmaceuticals GmbH (DE) 2025-09-03 EP disclosed
CN-120129534-A Radiopharmaceutical composition 日本医事物理股份有限公司 2025-06-10 CN disclosed
US-20250059379-A1 PAINTS CONTAINING DRIERS BASED ON VANADIUM COMPOUNDS BEARING VARIOUS ACID ANIONS BORCHERS GMBH (DE) 2025-02-20 US disclosed
US-20240417590-A1 PROCESS FOR IMPROVING RESIN PERFORMANCE USING LEWIS ACIDS BORCHERS GMBH (DE) 2024-12-19 US disclosed
US-20240368378-A1 PROCESS FOR IMPROVING RESIN PERFORMANCE BORCHERS GMBH (DE) 2024-11-07 US disclosed
EP-4453106-A1 PAINTS CONTAINING DRIERS BASED ON VANADIUM COMPOUNDS BEARING VARIOUS ACID ANIONS Borchers GmbH (DE) 2024-10-30 EP disclosed
US-20240316228-A1 RADIOACTIVE COMPLEX OF DEGLYCOSYLATED ANTIBODY AND RADIOACTIVE PHARMACEUTICAL PRODUCT NIHON MEDI-PHYSICS CO., LTD. (JP) 2024-09-26 US disclosed
CN-118647679-A Coating containing a drier based on vanadium compounds with various acid anions 博奇斯有限公司 2024-09-13 CN disclosed
EP-4408942-A1 PROCESS FOR IMPROVING RESIN PERFORMANCE USING LEWIS ACIDS Borchers GmbH (DE) 2024-08-07 EP disclosed
CN-118382464-A Stabilized radiopharmaceutical compositions 日本医事物理股份有限公司 2024-07-23 CN disclosed
WO-2023117421-A1 PAINTS CONTAINING DRIERS BASED ON VANADIUM COMPOUNDS BEARING VARIOUS ACID ANIONS BORCHERS GMBH (DE) 2023-06-29 WO disclosed
US-20230203336-A1 Paints Containing Driers Based on Vanadium Compounds Bearing Anions of Sulfonic Acids as Counter Ions BORCHERS GMBH (DE) 2023-06-29 US disclosed
EP-4172283-A1 PAINTS CONTAINING DRIERS BASED ON VANADIUM COMPOUNDS BEARING ANIONS OF SULFONIC ACIDS AS COUNTER IONS Borchers GmbH (DE) 2023-05-03 EP disclosed
WO-2023052294-A1 PROCESS FOR IMPROVING RESIN PERFORMANCE USING LEWIS ACIDS BORCHERS GMBH (DE) 2023-04-06 WO disclosed
WO-2023030700-A1 PROCESS FOR IMPROVING RESIN PERFORMANCE BORCHERS GMBH (DE) 2023-03-09 WO disclosed
WO-2023033022-A1 RADIOACTIVE COMPLEX OF DEGLYCOSYLATED ANTIBODY AND RADIOACTIVE PHARMACEUTICAL PRODUCT 日本メジフィジックス株式会社 2023-03-09 WO disclosed
CN-115720590-A Paint comprising a drier based on a vanadium compound containing a sulphonic anion as a counterion 博奇斯有限公司 2023-02-28 CN disclosed
US-11518834-B2 Radically polymerizable compositions Polynt Composites USA, Inc. (US) 2022-12-06 US disclosed
WO-2022224980-A1 RADIOACTIVE COMPLEX OF ANTI-CD20 ANTIBODY, AND RADIOPHARMACEUTICAL 日本メジフィジックス株式会社 2022-10-27 WO disclosed
WO-2022211051-A1 RADIOACTIVE COMPLEX OF ANTI-EGFR ANTIBODY, AND RADIOPHARMACEUTICAL 日本メジフィジックス株式会社 2022-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316228-A1 RADIOACTIVE COMPLEX OF DEGLYCOSYLATED ANTIBODY AND RADIOACTIVE PHARMACEUTICAL PRODUCT FCGR2A, FCGR1A, FCGR3B CYP1A2 3044/4885CYP2C19 2169/4885KMT2A 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.